Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2013

View Archived Issues

EZH2 inhibition as a promising approach for treating CML

Discovery of a BTK inhibitor for the treatment of lupus-related renal disease

Amarantus expands intellectual property portfolio for MANF

Perrigo's acquisition of Elan Corporation completed

America Stem Cell changes name

Ivy Foundation awards grant to support brain cancer research

FDA grants orphan drug status to metadoxine in fragile X syndrome

Pleiotropic pathway modulator CC-122 evaluated in first-in-human trial

MAPK 14 inhibitor devised for use as a CNS probe

Chinese group presents new S1P1 receptor ligands

Researchers at Bayer Schering Pharma disclose new GLUT1 inhibitors for cancer

Novel tankyrase inhibitors synthesized by Roche

Novel BACE1 inhibitors for Alzheimer's disease reported by Lundbeck

Astex Therapeutics patents novel FGFR inhibitors

BioCryst submits NDA for peramivir to treat influenza

Pozen to conduct comparative pharmacokinetic study of PA-8140/PA-32540

Eli Lilly and Boehringer Ingelheim submit NDA to FDA for new insulin glargine product

Auxilium Pharmaceuticals submits supplemental BLA to the FDA for Xiaflex

EMA accepts filing of MAA for cangrelor

Regulatory application filed for nivolumab in malignant melanoma

Tretten approved in the U.S. for congenital FXIII A-subunit deficiency

Tafenoquine obtains FDA breakthrough therapy designation

Cervarix two-dose schedule receives European marketing authorization

EMA accepts dalbavancin MAA for review

FDA approves Orenitram for PAH

Actelion's Opsumit granted marketing authorization in the E.U. for PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...